Convergent Therapeutics Inc., a clinical-stage biotechnology company, has announced the receipt of its first shipment of non-carrier added (n.c.a.) Actinium-225 (Ac-225) from Cardinal Health. This milestone supports the advancement of Convergent's lead asset, CONV01-α, currently in a Phase 2 clinical trial as a potential treatment for prostate cancer.
Addressing Unmet Needs in Prostate Cancer Treatment
Prostate cancer remains a significant health challenge, with a substantial need for more effective and targeted therapies. CONV01-α, a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225, represents a promising approach. PSMA is highly overexpressed in prostate cancer cells, making it a validated target for therapeutic intervention.
CONV01-α: A Novel Radioantibody Approach
CONV01-α leverages a humanized monoclonal antibody to target PSMA, delivering Ac-225 directly to cancer cells. Ac-225 is an alpha-emitting radionuclide that induces DNA double-strand breaks, leading to cancer cell death. The targeted delivery of alpha particles minimizes radiation exposure to healthy neighboring cells and tissues, potentially reducing off-target effects.
Overcoming Supply Chain Limitations
The availability of Ac-225 has historically been constrained by limited production capacity. This collaboration between Convergent and Cardinal Health addresses this challenge by increasing Ac-225 access, which is vital for advancing clinical trials and future therapeutic applications. "This generated Ac-225 supply represents a major shift in the supply chain for this critical radioisotope for the treatment of patients with cancer," said Philip Kantoff, MD, Co-founder and CEO of Convergent Therapeutics.
Clinical Development and Future Implications
The ongoing Phase 2 clinical trial (CONVERGE-01) is evaluating the safety and efficacy of CONV01-α in patients with prostate cancer. The results of this trial could pave the way for a new generation of radiopharmaceutical therapies that offer improved outcomes and reduced toxicity compared to existing treatments. Mike Pintek, President of Cardinal Health Nuclear & Precision Health Solutions, stated, "We look forward to increasing Ac-225 access to help advance the next generation of cancer treatment for patients."
